title: High-pressure NMR characterization of triacetyl-beta-cyclodextrin in supercritical carbon dioxide.
abstract: Cyclodextrins are used in many drug formulations since their cavities provide microenvironments where drug molecules can enter and form inclusion complexes for controlled drug delivery. Supercritical carbon dioxide (scCO(2)) is an alternative to organic solvents and a very attractive medium for the preparation of these inclusion complexes. The potential ability of triacetyl-beta-cyclodextrin (TA-beta-CD) to form inclusion complexes in addition to its high miscibility in liquid and scCO(2) could offer a chance for an economical and environmental friendly chemical processing. In this work, high-pressure NMR studies were performed in order to obtain information on the molecular structure and dynamics of TA-beta-CD in scCO(2) at 313.15 K and 20 MPa and its ability to form inclusion complexes under these conditions was studied. The influence of scCO(2) on a number of NMR spectral parameters, such as chemical shifts, spin-spin coupling constants, nuclear Overhauser effect (NOE) and spin-lattice relaxation (T(1)) has been studied. We unequivocally show for the first time structural changes of TA-beta-CD in scCO(2), like acetyl chain orientation and overall shape distortions that can affect its inclusion capability in this medium. The possibility of cavity self-closure is discussed and the results of two inclusion studies that support cavity self-closure, with the angiotensin-converting enzyme inhibitor, captopril, and the nonsteroid anti-inflammatory drug, flufenamic acid, are presented.
authors.affiliation: REQUIMTE, CQFB, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
authors.forename: G I
authors.initials: GI
authors.lastname: Ivanova
authors.forename: E R
authors.initials: ER
authors.lastname: Vão
authors.forename: M
authors.initials: M
authors.lastname: Temtem
authors.forename: A
authors.initials: A
authors.lastname: Aguiar-Ricardo
authors.forename: T
authors.initials: T
authors.lastname: Casimiro
authors.forename: E J
authors.initials: EJ
authors.lastname: Cabrita
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D002216:Captopril / Q000008:administration & dosage; D002245:Carbon Dioxide; D003505:Cyclodextrins / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D005439:Flufenamic Acid / Q000008:administration & dosage; D055772:Green Chemistry Technology; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D015394:Molecular Structure; D011312:Pressure
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003505:Cyclodextrins; D004337:Drug Carriers; D002245:Carbon Dioxide; D005439:Flufenamic Acid; D002216:Captopril